Su Metcalfe, PhD, Founder & CSO Discovered the role of LIF in immunity. Group Leader and recipient of £2m competitive academic grant funding for proof of concept of the LIF-carrying nanoparticles. Co-owner of two patents on the LIF-carrying nanoparticles with Yale University. Negotiated world-wide exclusive rights in the LIF-carrying nanoparticles with Yale University.
- Global Rolex Award 2016 - shortlisted.
- Cambridge Business School - Woman Entrepreneur of the Year 2017.
- Merck’s global GMSI award plus matched Innovate-UK Smart Award - £250k
- Innovate-UK BioMedical Catalyst Award 2017 -2019 - £1m.
- Finalist for the Nano Medicine award 2017 for the most significant potential breakthrough technology for healthcare globally.
Florian Kemmerich, BA & MSc, Co-Founder and Board Chair leverages his extensive background in start-ups in biotech, medical devices and life sciences to help build and reposition organizations in the competitive global marketplace. Passionate about translational medicine, growth factors, stem cells and biologics, Florian has a proven record of accomplishment of building and leading innovative and effective commercial stage companies.
Olivier Jarry, MSc MEng MBA, Co-Founder and Director was a partner/Advisor of several investment funds and strategy groups, and Board Member of organizations in healthcare and digital health before joining LIFNanoRx Ltd. Olivier combines expertise in biopharma and biotechnologies over the past 20 years, with business design and management over the last 32 years on 5 continents. Olivier has worked on strategy and planning for biologics at Bristol-Myers Squibb, synthetic biology and gene therapy at Intrexon, expanding existing businesses and building new businesses as a senior executive at Novartis, Bayer and as a strategy consultant at Pfizer, J&J, Sanofi, GSK.
Andrew Wood, BSc, CFO, holds a 1st Class Hons degree from Oxford in Biochemistry. Andrew has extensive finance and commercial experience in startup, early stage and established businesses. He is now building a portfolio of early stage life sciences companies. Previously he was CFO of Oxford Biomedica.